endocrine/exocrine glands
|
• mice injected with an adenovirus expressing cre recombinase (AdCre) in the ovarian bursa rapidly develop primary ovarian tumors
• treatment of isolated tumor cells with the pan-class I PI3K inhibitor, Buparlisib, results in reduced tumor cell viability
• treatment of mice with Buparlisib for 3 weeks starting at week 4 post AdCre injection extends the median latency period of ovarian tumors by 3.5 weeks
|
|
• ovarian tumors of intrabursally AdCre injected mice are predominately solid with some papillary areas, exhibit elongated spindle-shaped cells with vacuolated cytoplasm embedded in hyalinized matrix, appear poorly differentiated and highly disorganized, and have a hobnail appearance, indicating they resemble human ovarian clear-cell carcinoma
|
homeostasis/metabolism
immune system
|
• AdCre treated mice that have tumors exhibit high levels of secreted IL-6 in body fluids and ascitic fluid aspirates
|
neoplasm
|
• mice injected with an adenovirus expressing cre recombinase (AdCre) in the ovarian bursa rapidly develop primary ovarian tumors
• treatment of isolated tumor cells with the pan-class I PI3K inhibitor, Buparlisib, results in reduced tumor cell viability
• treatment of mice with Buparlisib for 3 weeks starting at week 4 post AdCre injection extends the median latency period of ovarian tumors by 3.5 weeks
|
|
• ovarian tumors of intrabursally AdCre injected mice are predominately solid with some papillary areas, exhibit elongated spindle-shaped cells with vacuolated cytoplasm embedded in hyalinized matrix, appear poorly differentiated and highly disorganized, and have a hobnail appearance, indicating they resemble human ovarian clear-cell carcinoma
|
|
• peritoneal metastases are seen in about 50% of mice injected with AdCre in the ovarian bursa
|
reproductive system
|
• mice injected with an adenovirus expressing cre recombinase (AdCre) in the ovarian bursa rapidly develop primary ovarian tumors
• treatment of isolated tumor cells with the pan-class I PI3K inhibitor, Buparlisib, results in reduced tumor cell viability
• treatment of mice with Buparlisib for 3 weeks starting at week 4 post AdCre injection extends the median latency period of ovarian tumors by 3.5 weeks
|
|
• ovarian tumors of intrabursally AdCre injected mice are predominately solid with some papillary areas, exhibit elongated spindle-shaped cells with vacuolated cytoplasm embedded in hyalinized matrix, appear poorly differentiated and highly disorganized, and have a hobnail appearance, indicating they resemble human ovarian clear-cell carcinoma
|